Cargando…
Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab
Introduction: The combination of immunotherapy and targeted therapy is currently marking a new era in the treatment of renal cancer. The latest clinical guidelines recommend the use of drug combinations for the first-line treatment of advanced renal cancer. The aim of this review is to compare the e...
Autores principales: | Niewada, Maciej, Macioch, Tomasz, Konarska, Magdalena, Mela, Aneta, Goszczyński, Adam, Przekopińska, Bogusława, Rajkiewicz, Karolina, Wysocki, Piotr, Krzakowski, Maciej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020696/ https://www.ncbi.nlm.nih.gov/pubmed/36937206 http://dx.doi.org/10.3389/fphar.2022.1063178 |
Ejemplares similares
-
STARLITE 1: Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC
por: Hasanov, Elshad, et al.
Publicado: (2023) -
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2021) -
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
por: Lheureux, Stephanie, et al.
Publicado: (2022) -
Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma
por: Jansen, Caroline S., et al.
Publicado: (2023) -
Cabozantinib/ipilimumab/nivolumab interaction: Haemophagocytic lymphohistiocytosis: case report
Publicado: (2021)